Literature DB >> 24390741

Harnessing the immune system for the treatment of breast cancer.

Xinguo Jiang1.   

Abstract

Standard treatment options for breast cancer include surgery, chemotherapy, radiation, and targeted therapies, such as adjuvant hormonal therapy and monoclonal antibodies. Recently, the recognition that chronic inflammation in the tumor microenvironment promotes tumor growth and survival during different stages of breast cancer development has led to the development of novel immunotherapies. Several immunotherapeutic strategies have been studied both preclinically and clinically and already have been shown to enhance the efficacy of conventional treatment modalities. Therefore, therapies targeting the immune system may represent a promising next-generation approach for the treatment of breast cancers. This review will discuss recent findings that elucidate the roles of suppressive immune cells and proinflammatory cytokines and chemokines in the tumor-promoting microenvironment, and the most current immunotherapeutic strategies in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24390741      PMCID: PMC3891115          DOI: 10.1631/jzus.B1300264

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  156 in total

1.  Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers.

Authors:  M S Shin; H S Kim; S H Lee; W S Park; S Y Kim; J Y Park; J H Lee; S K Lee; S N Lee; S S Jung; J Y Han; H Kim; J Y Lee; N J Yoo
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

Review 2.  Eicosanoids and adipokines in breast cancer: from molecular mechanisms to clinical considerations.

Authors:  Samar Basu; Rachida Nachat-Kappes; Florence Caldefie-Chézet; Marie-Paule Vasson
Journal:  Antioxid Redox Signal       Date:  2012-08-29       Impact factor: 8.401

Review 3.  Neutralizing tumor-promoting chronic inflammation: a magic bullet?

Authors:  Lisa M Coussens; Laurence Zitvogel; A Karolina Palucka
Journal:  Science       Date:  2013-01-18       Impact factor: 47.728

Review 4.  Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy.

Authors:  Madhuri Kakarala; Max S Wicha
Journal:  J Clin Oncol       Date:  2008-06-10       Impact factor: 44.544

5.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Authors:  C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

6.  Stromal gene expression predicts clinical outcome in breast cancer.

Authors:  Greg Finak; Nicholas Bertos; Francois Pepin; Svetlana Sadekova; Margarita Souleimanova; Hong Zhao; Haiying Chen; Gulbeyaz Omeroglu; Sarkis Meterissian; Atilla Omeroglu; Michael Hallett; Morag Park
Journal:  Nat Med       Date:  2008-04-27       Impact factor: 53.440

7.  Wiskott-Aldrich syndrome protein regulates leukocyte-dependent breast cancer metastasis.

Authors:  Dan Ishihara; Athanassios Dovas; Lorena Hernandez; Maria Pozzuto; Jeffrey Wyckoff; Jeffrey E Segall; John S Condeelis; Anne R Bresnick; Dianne Cox
Journal:  Cell Rep       Date:  2013-08-01       Impact factor: 9.423

8.  The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer.

Authors:  S Muenst; S D Soysal; F Gao; E C Obermann; D Oertli; W E Gillanders
Journal:  Breast Cancer Res Treat       Date:  2013-06-12       Impact factor: 4.872

9.  Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies.

Authors:  Inge Verbrugge; Jim Hagekyriakou; Leslie L Sharp; Mara Galli; Alison West; Nicole M McLaughlin; Hélène Duret; Hideo Yagita; Ricky W Johnstone; Mark J Smyth; Nicole M Haynes
Journal:  Cancer Res       Date:  2012-05-08       Impact factor: 12.701

10.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.

Authors:  Srinivas Nagaraj; Kapil Gupta; Vladimir Pisarev; Leo Kinarsky; Simon Sherman; Loveleen Kang; Donna L Herber; Jonathan Schneck; Dmitry I Gabrilovich
Journal:  Nat Med       Date:  2007-07-01       Impact factor: 53.440

View more
  10 in total

1.  Macrophage-produced IL-10 limits the chemotherapy efficacy in breast cancer.

Authors:  Xinguo Jiang
Journal:  J Zhejiang Univ Sci B       Date:  2015-01       Impact factor: 3.066

Review 2.  Pesticides as the drivers of neuropsychotic diseases, cancers, and teratogenicity among agro-workers as well as general public.

Authors:  Seema Patel; Sushree Sangeeta
Journal:  Environ Sci Pollut Res Int       Date:  2018-11-08       Impact factor: 4.223

3.  Berberine-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species generation and mitochondrial-related apoptotic pathway.

Authors:  Juan Xie; Yinyan Xu; Xinyan Huang; Yanni Chen; Jing Fu; Mingming Xi; Li Wang
Journal:  Tumour Biol       Date:  2014-10-29

4.  Green tea polyphenols induce cell death in breast cancer MCF-7 cells through induction of cell cycle arrest and mitochondrial-mediated apoptosis.

Authors:  Shu-Min Liu; Shi-Yi Ou; Hui-Hua Huang
Journal:  J Zhejiang Univ Sci B       Date:  2017 Feb.       Impact factor: 3.066

Review 5.  Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer.

Authors:  Nirmala Chandralega Kampan; Mutsa Tatenda Madondo; Orla M McNally; Michael Quinn; Magdalena Plebanski
Journal:  Biomed Res Int       Date:  2015-06-07       Impact factor: 3.411

6.  Macrophages in solid organ transplantation.

Authors:  Xinguo Jiang; Wen Tian; Yon K Sung; Jin Qian; Mark R Nicolls
Journal:  Vasc Cell       Date:  2014-03-11

Review 7.  Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy.

Authors:  Javad Sharifi-Rad; Cristina Quispe; Jayanta Kumar Patra; Yengkhom Disco Singh; Manasa Kumar Panda; Gitishree Das; Charles Oluwaseun Adetunji; Olugbenga Samuel Michael; Oksana Sytar; Letizia Polito; Jelena Živković; Natália Cruz-Martins; Marta Klimek-Szczykutowicz; Halina Ekiert; Muhammad Iqbal Choudhary; Seyed Abdulmajid Ayatollahi; Bekzat Tynybekov; Farzad Kobarfard; Ana Covilca Muntean; Ioana Grozea; Sevgi Durna Daştan; Monica Butnariu; Agnieszka Szopa; Daniela Calina
Journal:  Oxid Med Cell Longev       Date:  2021-10-18       Impact factor: 6.543

Review 8.  The Role of Extracellular Matrix Proteins in Breast Cancer.

Authors:  Arkadiusz Lepucki; Kinga Orlińska; Aleksandra Mielczarek-Palacz; Jacek Kabut; Pawel Olczyk; Katarzyna Komosińska-Vassev
Journal:  J Clin Med       Date:  2022-02-25       Impact factor: 4.241

Review 9.  Exploring new pathways in endocrine-resistant breast cancer.

Authors:  Inês Soares de Pinho; Catarina Abreu; Inês Gomes; Sandra Casimiro; Teresa Raquel Pacheco; Rita Teixeira de Sousa; Luís Costa
Journal:  Explor Target Antitumor Ther       Date:  2022-06-20

Review 10.  Graft microvascular disease in solid organ transplantation.

Authors:  Xinguo Jiang; Yon K Sung; Wen Tian; Jin Qian; Gregg L Semenza; Mark R Nicolls
Journal:  J Mol Med (Berl)       Date:  2014-06-01       Impact factor: 4.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.